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Myxoid/round cell liposarcoma (MRCL), unlike other soft tissue sarcomas, has been associated with unusual pattern of metastasis
to extrapulmonary sites. In an attempt to elucidate the clinical features of MRCL with metastatic lesions, 58 cases, from the
medical database of Keio University Hospital were used for the evaluation. 47 patients (81%) had no metastases, whereas 11
patients (11%) had metastases during their clinical course. Among the 11 patients with metastatic lesions, 8 patients (73%) had
extrapulmonary metastases and 3 patients (27%) had pulmonary metastases. Patients were further divided into three groups;
without metastasis, with extrapulmonary metastasis, and with pulmonary metastasis. When the metastatic patterns were stratiﬁed
according to tumor size, there was statistical signiﬁcance between the three groups (P = 0.028). The 8 cases with extrapulmonary
metastases were all larger than 10cm. Similarly, histological grading had a signiﬁcant impact on metastatic patterns (P = 0.027). 3
cases with pulmonary metastatic lesions were all diagnosed as high grade. In conclusion, large size and low histological grade were
signiﬁcantly associated with extrapulmonary metastasis.
1.Introduction
Liposarcoma is one of the most common subtypes among
soft tissue sarcomas constituting 9–18% of all cases [1]. The
incidence peaks between the 4th and 5th decades of life
and there is a slight male predominance. The World Health
Organization recognizes four subtypes: well diﬀerentiated,
dediﬀerentiated, myxoid/round cell, and pleomorphic. The
myxoid/round cell subtype is among the most prevalent and
typically occurs in younger individuals [2]. It characteristi-
cally occurs in the deep-seated soft tissues of the extremities,
especially in the thigh which comprises two-thirds of the
group.
Another important distinction from other types of lipo-
sarcomas is that MRCL is associated with an unusual pattern
ofmetastasistobonesuchasspineandothersofttissuessuch
as retroperitoneum, limb, and axilla [2, 3]. Other soft tissue
sarcomas tend to metastasizes to the lung, while other sites
are typically involved in advanced stages of the disease [2, 3].
Although the predilection of MRCL for extrapulmonary
metastases is widely accepted, there is no data regarding
which MRCL metastasizes to the lung and which MRCL
metastasizes to extrapulmonary sites. The purpose of this
study is to elucidate the clinical features of MRCL with
metastatic lesions.2 Sarcoma
2.MaterialsandMethods
2.1. Patients. We evaluated 58 cases of MRCL from the
medical database of Keio University Hospital between 1985
and 2010. Median followup was 78 months (range; 3–290
months). All primary tumors were imaged with MRI.
All but one primary tumor were managed by surgical
treatment. Radiotherapy and chemotherapy were utilized
on a case-by-case basis. All patients were followed clinically
and with radiographic surveillance (chest X-ray and/or
CT) for metastasis. Local recurrence was monitored by
physical examination and MRI. Additional screening tests,
ordered at the discretion of the physician to rule out extra-
pulmonary metastasis, included bone scintigraphy, CT of
abdomen/pelvis, and MRI of the spine.
2.2. Deﬁnitions. In order to determine the clinicopatho-
logical features of metastasis in MRCL, we divided pa-
tients into three groups; (1) without metastasis, (2) with
extrapulmonary metastasis, and (3) with pulmonary metas-
tasis. If patients had both pulmonary and nonpulmonary
metastases during clinical courses, we grouped them accord-
ing to their ﬁrst metastasis site.
Tumors demonstrating a round cell component of less
than 5% of tumor volume were designated as low grade
(Figure 1(a)) and tumors with round cell component of
higher than 5% of tumor volume were considered high grade
(Figure 1(b)) as described previously [4]. The percentage of
round cells was estimated by scanning all individual sections
(average 1 block/1cm3 of tumor) of the resected specimen.
The percentage of round cell component was estimated
by scanning all individual sections, using the entire tumor
volume as a denominator as described previously by other
authors [4, 5].
2.3. Demographics. Of the 58 patients with MRCL identiﬁed
from our sarcoma database, 33 were male and 25 were
female. Median age at presentation was 46 years old (range;
18–80 years). 19 patients (33%) had tumors greater than
10cm in size. 39 of 52 patients (75%) had tumors beneath
the subcutaneous layer. 48 patients (83%) had the primary
tumor in the extremities and 10 (17%) in the trunk. The
most common site was the thigh occurring in 30 patients,
followed by lower leg in 9 patients, upper arm in 4 patients,
retroperitoneum in 2 patients, and 1 each of shoulder, elbow,
forearm, popliteal, foot, chest wall, groin, lower back, and
buttock.
2.4. Histology. 38 patients (66%) were diagnosed as low
grade MRCL, whereas the remaining 20 cases (34%) with
more than 5% of round cell morphology were diagnosed
as high grade MRCL. Within low grade MRCL, 21 patients
(36%) had pure myxoid component and 17 patients (29%)
had less than 5% of round cell area.
2.5. Operative Treatment. All but one patient underwent
surgical resections. Wide or radical resection was achieved in
40 patients (69%), whereas the remaining patients had
(a)
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Figure 1: (a) Photomicrograph of low-grade MRCL. (b) Photomi-
crograph of high-grade MRCL.
marginal (16 patients, 28%) or intralesional resections (one
patient, 13%).
2.6.Chemotherapy. Twenty-nine(50%)of58MRCLpatients
received variable chemotherapy for the primary tumors: 3
as neoadjuvant therapy, 21 as adjuvant therapy, 5 as neo-
adjuvant and adjuvant therapy. The details of regimens
were available in 25 patients. Treatments were highly het-
erogeneous. 5 diﬀerent regimens were administered with
doxorubicin-containing regimens comprising the largest
subgroup; doxorubicin + ifosfamide: total 17 courses in 11
patients, doxorubicin + cisplatin/ifosfamide + etoposide:
total 18 courses in 10 patients, vincristine + doxorubicin +
cyclophosphamide/ifosfamide + etoposide: total 4 courses
in 2 patients. The remaining regimens were comprised of
conventional or experimental agents; cisplatin + etoposide: 3
courses in 2 patients, ifosfamide: 2 courses in one patient.
Response data were not available.
2.7. Radiotherapy. We performed external radiation therapy
for the high-risk cases such as close surgical margin or huge
tumor size. Thirteen (22%) of 58 MRCL patients received
radiotherapytotheprimarylesions:2asneoadjuvant(40Gy)
and 11 as adjuvant (50–68Gy).Sarcoma 3
2.8. Data. Age, gender, tumor location, size, depth, histo-
logical grade (low versus high), surgical margin, addition
of radiotherapy (yes versus no), addition of chemotherapy
(yes versus no), local recurrence, and clinical outcome were
analyzed for its correlation to metastasis. We designated
initial time as the date of initial diagnosis of MRCL and ﬁnal
time as the date of last visit.
2.9. Statistical Analysis. Categorical data were analyzed with
chi-square test (William’s correction) using StatMate IV
(ATMS Co. Ltd., Tokyo, Japan). Survival data were calculated
using Kaplan-Meier method. Results with P<0.05 were
considered statistically signiﬁcant.
3. Results
47 patients (81%) had no metastases, whereas 11 patients
(19%) had metastases during their clinical course. Local
recurrence occurred in 5 patients (9%). All local recurrences
wereresectedwithwidemargins.Amongthe11patientswith
metastatic lesions, 8 patients (73%) had extrapulmonary
metastases and 3 (27%) had pulmonary metastases. All 8 pa-
tients with extrapulmonary metastasis had no pulmonary
metastases during their clinical course. One of 3 patients
withpulmonarymetastasisexperiencedbothpulmonaryand
extrapulmonary metastasis.
When the metastatic patterns were stratiﬁed according
to tumor size (<10cm or ≥10cm), there was statistical sig-
niﬁcance between the three groups (P = 0.028) (Table 1). Of
the 47 cases without metastasis, 14 (38%) were larger than
10cm. The 8 cases with extrapulmonary metastases were all
larger than 10cm, whereas only 1 case (33%) was larger than
10cm in pulmonary metastatic group (Figure 2(a)). Sim-
ilarly, histological grading had a signiﬁcant impact on
metastasis patterns (P = 0.027) (Table 1). Of the 8 cases with
extrapulmonary metastases, 4 (50%) were pathologically
diagnosed as high grade MRCL, whereas 3 cases with pul-
monary metastases were all diagnosed as high grade MRCL
(Figure 2(b)). Surgical margin, radiotherapy, and local re-
currence had no signiﬁcant eﬀect on metastatic patterns
(Table 2). Chemotherapy was performed in 20 cases (43%)
without metastases, 6 cases (75%) with extrapulmonary
metastases, and 3 cases (100%) with pulmonary metastases.
Chemotherapy was not eﬀective in reducing disease-free sur-
vival rate, but implementation of chemotherapy had statisti-
callysigniﬁcantinﬂuenceonmetastaticpatterns(P = 0.003).
Of the 58 patients, 43 were continuously disease free (CDF),
7 had no evidence of disease (NED), 1 was alive with
disease (AWD), and 7 were dead of disease (DOD). In
8 patients with extrapulmonary metastases, 4 (50%) were
N E D ,1w a sA W D ,a n d3( 3 8 % )w e r eD O D .T h e r ew a sn o
survivor with pulmonary metastases (P<0.001) (Table 2).
Duration from primary surgery to ﬁrst metastasis was longer
in patients with extrapulmonary metastases (median 55
months) compared to patients with pulmonary metastases
(median 16 months) (P = 0.069). The absolute overall
survival rate was 86% (Figure 3(a)). The overall survival rate
was signiﬁcantly better for patients with extrapulmonary
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Figure 2: (a) Correlation of metastatic pattern to tumor size.
Whenthemetastaticpatternswerestratiﬁedaccordingtotumorsize
(<10cm or ≥10cm), there was statistical signiﬁcance between the
groups (P = 0.028). Of the 47 cases without metastases, 14 (38%)
werelargerthan10cm.The8caseswithextrapulmonarymetastases
were all larger than 10cm. Only 1 case was larger than 10cm
in the pulmonary metastatic group. (b) Correlation of metastatic
patterntohistological grade.Histological grading(loworhigh)had
a signiﬁcant impact on metastasis patterns (P = 0.027). Of the 8
cases with extrapulmonary metastases, 4 (50%) were pathologically
diagnosed as low-grade MRCL and 4 (50%) as high-grade MRCL.
The 3 cases with pulmonary metastatic lesions were all diagnosed as
high-grade MRCL.4 Sarcoma
Table 1: Inﬂuence of pathologic variables on metastatic pattern.
Parameters Total Absence of metastasis Extrapulmonary metastasis Pulmonary metastasis P value
Patients (No.) 58 47 8 3
Age at diagnosis
Median age (range) 46 (18–80) 44 (18–80) 51 (37–66) 58 (32–72) NS
≤45 28 24 3 1 0.699529
>45 30 23 5 2
Gender
Male 33 27 3 3 NS
Female 25 20 5 0 0.127731
Tumor size
Median size (range) 9.3 (1.2–25) 8.7 (1.2–20) 15.5 (10–25) 9 (4–14) P<0.05
≥10cm 31 29 0 2 0.027573
≥10cm 19 14 4 1
unknown 8 4 4 0
Tumor depth
Superﬁcial 13 11 1 2 NS
Deep 39 32 5 1 0.351308
U n k n o w n 6 420
Tumor site
Extremity 48 41 5 2 NS
Trunk 10 6 3 1 0.29337
Histological grade
Low grade 38 34 4 0 P<0.05
High grade 20 13 4 3 0.026703
metastases(63%)comparedtothosewithpulmonarymetas-
tases (0%) (Figure 3(b)).
4. Discussion
In contrast to other soft tissue sarcomas which metastasize
primarily to the lung, MRCL is associated with an unusual
pattern of metastasis. Previous reports have shown metas-
tases of MRCL to extrapulmonary sites, including the retro-
peritoneum, subcutaneous soft tissue and bone [2, 3, 5, 6].
Antonescu and Blair reported that MRCL in particular tends
tospreadtoothersofttissuesitesincludingretroperitoneum,
thorax, and extremity before metastasizing to the lung
[4, 5, 7]. Also, in the previous large series of MRCL,
extrapulmonary metastatic rate in MRCL was 17–30% and
common sites of extrapulmonary metastases were bone,
soft tissue of extremity, retroperitoneum, abdomen, and
chest wall [2, 6, 8, 9]. Skeletal metastasis has recently been
reportedasthemostcommonsiteofmetastasisinMRCL[2].
Schwab et al. identiﬁed 8 patients with skeletal metastases on
radiographic ﬁndings in a population of 184 patients with
MRCL, an incidence of 4.3% [2]. Schwab et al. reported that
more than half (56%) of the total metastatic sites represent
skeletal metastases,70% in the absenceof pulmonary spread,
and a high incidence of metastasis to the spine [2].
MRCL contains the speciﬁc t (12; 16) chromosomal
translocation, which results in rearrangement of the TLS
and CHOP genes that is clone speciﬁc at DNA level [10–
12]. Three common forms of the TLS-CHOP fusion have
been described, diﬀering by the presence or absence of TLS
exons 6–8 in the fusion product. Type I includes TLS exon
6 and 7 in the fusion, type II consists of TLS exon 1–5
fused to CHOP exon 2, and type III fuses TLS exons 1–8
to CHOP e x o n2[ 5]. A speciﬁc TLS-CHOP fusion gene
resulting from the t (12; 16) is present in at least 95% of
MRCL [5]. 85% of the patients who developed bone
metastases showed a type II TLS-CHOP fusion transcript
[2]. Ogose et al. reported that the reason for the high
incidence of extrapulmonary metastases in MRCL is unclear,
but an abundance of fat cells in metastatic sites, such as
subcutaneous tissue, retroperitoneum, bone marrow, and
epidural space, may contribute to the high incidence of
these unusual metastases [13]. In our study, extrapulmonary
metastases rate in MRCL was 14%. Common locations for
extrapulmonary metastases were bone and soft tissue of
extremities, similar to the previous studies (Table 3).
MRCL patients have been reported to present more
commonly with multifocal disease, either synchronous or
metachronous, compared to other soft tissue sarcomas [7].
Multifocal presentation, deﬁned as the presence of tumor
at two or more anatomically separate sites, before theSarcoma 5
Table 2: Inﬂuence of treatment variables on metastatic patterns.
Parameters Total Absence of metastasis Extrapulmonary metastasis Pulmonary metastasis P value
Patients (No.) 58 47 8 3
Surgical margin
Intralesional 1 1 0 0
Marginal 16 12 3 1 NS
Wide 40 34 4 2 0.700905
Radiotherapy
Y e s 1 3 931 N S
No 45 38 5 2 0.550657
Chemotherapy
Yes 29 20 6 3 P<0.05
No 29 27 2 0 0.0037966
Local recurrence
Y e s 5 311 N S
No 53 44 7 2 0.51357
Disease free
Yes 50 4 0 P<0.001
No 8 4 3 4.40E −05
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Figure 3: Survival rate. (a) The absolute overall survival rate
was 86%. (b) The overall survival rate was signiﬁcantly better for
patients with extrapulmonary metastasis (63%) compared to those
with pulmonary metastasis (0%) (P<0.001).
manifestation of disease in sites where sarcomas usually
metastasize (e.g., lungs) occurs in about 1% of extremity soft
tissue sarcomas [7].
An interesting question is whether these extrapulmonary
tumors in fact represent metastatic disease versus sites of
synchronous or metachronous primary disease [8]. Tedeschi
proposed the concept of a “pluricentric anlage” or “inci-
dental stimulation of undiﬀerentiated mesenchymal cells”
due to altered lipid metabolism [10]a sa ne x p l a n a t i o nt o
why patients he observed had multiple lipomatous tumors
in fat-bearing soft tissue locations. An analogy has been
drawn between this phenomenon and the clinical presen-
tation of multiple subcutaneous nodules in patients with
neuroﬁbromatosis [11]. Smith et al. analyzed the genomic
rearrangements of TLS, CHOP,o rEWS in six patients
and conﬁrmed the monoclonal origin of multifocal MRCL
[4]. They concluded that this unusual clinical phenomenon
most likely represents a pattern of presumably hematoge-
nous metastasis to other soft tissue sites, by tumor cells
seemingly incompetent to seed the lungs [4]. Deﬁnitive
diﬀerentiation between metastatic disease and synchronous
or metachronous primary disease is elusive and likely will
becomepossibleonlybymolecularbiologicanalysisoftumor
clonal heterogeneity [12].
Prognostic factors of MRCL have been described in
severalpreviousstudies.Age(>45years)[6],largetumorsize
(≥10cm) [14, 15], percentage of round cell diﬀerentiation
(≥5%) [4, 15], and presence of tumor necrosis [6] were asso-
ciated with a poor prognosis. Antonescu et al. also sought to
evaluatethepotentialimpactofTLS-CHOP fusiontranscript
structure on clinical outcome in 82 cases of localized
MRCL [5]. They concluded that in contrast to some other
translocation associated sarcomas, such as Ewing sarcoma,6 Sarcoma
Table 3: Comparison between previous and current study.
Year Author No. of
cases
Metastatic
rate
Extrapulmonary
metastatic rate
Pulmonary
metastatic rate
Common sites of the
extrapulmonary metastases
2007 Schwab JH 230 31% 17% 14% Bone, Soft tissue, Abdomen
1999 Spillane AJ 50 — 20% — Abdomen, Retroperitoneum
1997 Pearlstone DB 102 32% 30% 2% Retroperitoneum, Chest wall
1996 Kilpatrick SE 95 35% — — Retroperitoneum, Abdomen,
Chest wall
2010 Current study 58 19% 14% 5% Bone, Soft tissue
synovial sarcoma, and rhabdomyosarcoma, the molecular
variability of TLS-CHOP fusion transcript structure does
not appear to have a signiﬁcant impact on clinical outcome
in localized MRCL [5]. However, high histological grade
(≥5% round cell component), presence of necrosis, and
P53 overexpression were independent predictors of unfavor-
able outcome in localized MRCL [5]. To our knowledge,
parameters that inﬂuence the pattern of metastases have not
been reported to date. Our results suggest that tumor size,
histological grade, and implementation of chemotherapy
have signiﬁcant inﬂuence on metastatic patterns. Large
tumor size and low histological grade were signiﬁcantly
associated with extrapulmonary metastasis. Also, presence of
chemotherapy was signiﬁcantly associated with metastasis,
but there is a bias here in that higher rate of chemotherapy
was performed on patients with high-grade tumors: 15 of 20
patients (75%) compared to patients with low-grade tumors:
14 of 38 patients (37%). Chemotherapy was not eﬀective in
reducing disease-free survival rate.
In conclusion, extrapulmonary metastasis was observed
in 14% of the cases with MRCL. The bone was the most
common location for extrapulmonary metastasis. Large
tumor size and low histological grade were signiﬁcantly
associated with extrapulmonary metastasis. These ﬁndings
might lead to new diagnostic and treatment options for
MRCL.
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